



 FORM PTO-1449/A and PTO-modified PTO/SB/08 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.:	10/051497	ATTY. DOCKET NO.:	A0871.70000US01
	FILING DATE:	January 18, 2002	CONFIRMATION NO.:	1774
	APPLICANT:	Rong-Hwa Lin et al.		
	GROUP ART UNIT:	1644	EXAMINER:	Phillip Gambel

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		JP	09-227410	A	Sumitomo Pharmaceut Co. Ltd.	09-02-1997	in part
		WO	02/053700	A2	Bio-Technology General Corp.	07-11-2002	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER:

DATE CONSIDERED:

⁷ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

1644

Serial No.: 10/051497
Conf. No.: 1774

- 2 -

Art Unit: 1644

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Attorney Docket No.</u>
10/662,906	09/15/2003	Rong-Hwa Lin et al.	A0871.70001US00
11/125,837	05/10/2005	Rong-Hwa Lin et al.	A0871.70002US01
11/127,804	05/11/2005	Rong-Hwa Lin et al.	A0871.70003US02

The Applicant would like to bring to the Examiner's attention the enclosed search report from related International Application No. PCT/US04/29520.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

1052169.1

4/16/07



FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/051,497	ATTY. DOCKET NO.: A0871.70000US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: January 18, 2002	CONFIRMATION NO.: 1774
				APPLICANT: Rong-Hwa Lin et al.	
Sheet	1	of	1	GROUP ART UNIT: 1644	EXAMINER: P. Gambel

U.S. PATENT DOCUMENTS

Examiner's Initials [#]	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials [#]	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials [#]	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PL-		NIZET Y et al., The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. <i>Transplantation</i> 69 (7): 1420-1428 (2000).	
PL		TSUKAMOTO K et al., Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. <i>Cell Immunol.</i> 165:193-201 (1995).	


EXAMINER:	DATE CONSIDERED:
<i>Peter Gambel 4/16/07</i>	

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)		APPLICATION NO.: 10/051497	ATTY. DOCKET NO.: A0871.70000US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 18, 2002	CONFIRMATION NO.: 1774
		APPLICANT: Rong-Hwa Lin et al.	
Sheet	1	GROUP ART UNIT: 1644	EXAMINER: Phillip Gabel



U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,378,464		McEver	01-03-1995
		5,618,785		Heavner et al.	04-08-1997
		5,709,859		Aruffo et al.	01-20-1998
		5,710,123		Heavner et al.	01-20-1998
		5,808,025		Tedder et al.	09-15-1998
		5,834,425		Tedder et al.	11-10-1998
		5,972,625		Rosen et al.	10-26-1999
		6,056,956		Cobbold et al.	05-02-2000
		6,309,639		Cummings et al.	10-30-2001
		2002-0164336	A1	Harrison et al.	11-07-2002
		6,667,036		Cummings et al.	12-23-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
RG		HERRON MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. <i>Science</i> . 2000 Jun 2;288(5471):1653-6.	
M		LI F et al., Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies. <i>J. Biol. Chem.</i> 271(11):6342-6348 (1996).	
N		MOORE KL et al., P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. <i>J. Cell Biol.</i> 128(4):661-671 (1997).	

EXAMINER:	DATE CONSIDERED:
<i>Phillip Gabel 4/16/07</i>	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/051497	ATTY. DOCKET NO.: A0871.70000US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: January 18, 2002	CONFIRMATION NO.: 1774
				APPLICANT: Rong-Hwa Lin et al.	
Sheet	2	of	2	GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel

<i>PL</i>	SAKO D et al., Expression cloning of a functional glycoprotein ligand for P-selectin. <i>Cell</i> . 1993 Dec 17;75(6):1179-86.	
	TREMBLEAU S et al., Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. <i>J Immunol</i> . 1999 Sep 1;163(5):2960-8.	
	VACHINO G et al., P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. <i>J Biol Chem</i> . 1995 Sep 15;270(37):21966-74.	
	VELDMAN GM et al., Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand. <i>J Biol Chem</i> . 1995 Jul 7;270(27):16470-5.	
	WU P et al., Role of P-selectin and anti-P-selectin monoclonal antibody in apoptosis during hepatic/renal ischemia reperfusion injury. <i>World J. Gastroentero</i> 6(2):244-247 (2000).	
<i>PL</i>	YAGO T et al., IL-12 promotes the adhesion of NK cells to endothelial selectins under flow conditions. <i>J Immunol</i> . 1998 Aug 1;161(3):1140-5.	

EXAMINER:	DATE CONSIDERED:
<i>Phillip Gambel</i>	4/16/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]